Takeda gets rights to Theravance's GI candidate

Theravance Biopharma Inc. (NASDAQ:TBPH) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) a global license to develop and commercialize serotonin

Read the full 183 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE